Personalis price target raised to $10 from $8.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Personalis (PSNL) to $10 from $8.50 and keeps a Buy rating on the shares following the Q3 report. Management continues to expect reimbursement approval for two indications before 2026 and states that the demand for NeXT Personal and clinical trial sample testing continues to grow, the analyst tells investors in a research note.